Sen Pritha, Charini William A, Subbramanian Ramu A, Manuel Edwin R, Kuroda Marcelo J, Autissier Patrick A, Letvin Norman L
Beth Israel Deaconess Medical Center, Division of Viral Pathogenesis, 330 Brookline Ave., Boston, MA 02215, USA.
J Virol. 2008 Jan;82(2):805-16. doi: 10.1128/JVI.01038-07. Epub 2007 Oct 31.
To afford the greatest possible immune protection, candidate human immunodeficiency virus (HIV) vaccines must generate diverse and long-lasting CD8(+) T lymphocyte responses. In the present study, we evaluate T-cell receptor Vbeta (variable region beta) gene usage and a CDR3 (complementarity-determining region 3) sequence to assess the clonality of epitope-specific CD8(+) T lymphocytes generated in rhesus monkeys following vaccination and simian-human immunodeficiency virus (SHIV) challenge. We found that vaccine-elicited epitope-specific CD8(+) T lymphocytes have a clonal diversity comparable to those cells generated in response to SHIV infection. Moreover, we show that the clonal diversity of vaccine-elicited CD8(+) T-lymphocyte responses is dictated by the epitope sequence and is not affected by the mode of antigen delivery to the immune system. Clonal CD8(+) T-lymphocyte populations persisted following boosting with different vectors, and these clonal cell populations could be detected for as long as 4 years after SHIV challenge. Finally, we show that the breadth of these epitope-specific T lymphocytes transiently focuses in response to intense SHIV replication. These observations demonstrate the importance of the initial immune response to SHIV, induced by vaccination or generated during primary infection, in determining the clonal diversity of cell-mediated immune responses and highlight the focusing of this clonal diversity in the setting of high viral loads. Circumventing this restricted CD8(+) T-lymphocyte clonal diversity may present a significant challenge in the development of an effective HIV vaccine strategy.
为了提供尽可能强大的免疫保护,候选人类免疫缺陷病毒(HIV)疫苗必须产生多样且持久的CD8(+) T淋巴细胞反应。在本研究中,我们评估T细胞受体Vβ(可变区β)基因的使用情况和互补决定区3(CDR3)序列,以评估恒河猴在接种疫苗和感染猿猴-人类免疫缺陷病毒(SHIV)后产生的表位特异性CD8(+) T淋巴细胞的克隆性。我们发现,疫苗引发的表位特异性CD8(+) T淋巴细胞具有与SHIV感染所产生的细胞相当的克隆多样性。此外,我们表明,疫苗引发的CD8(+) T淋巴细胞反应的克隆多样性由表位序列决定,不受抗原递送至免疫系统方式的影响。用不同载体加强免疫后,克隆性CD8(+) T淋巴细胞群体持续存在,并且在SHIV攻击后长达4年都能检测到这些克隆细胞群体。最后,我们表明,这些表位特异性T淋巴细胞的广度会因强烈的SHIV复制而短暂集中。这些观察结果证明了由疫苗接种诱导或在初次感染期间产生的对SHIV的初始免疫反应在决定细胞介导的免疫反应的克隆多样性方面的重要性,并突出了在高病毒载量情况下这种克隆多样性的集中情况。规避这种受限的CD8(+) T淋巴细胞克隆多样性可能是有效HIV疫苗策略开发中的一项重大挑战。